First personalized therapy against Rheumatoid
Alibion AG
Incorporated
07.09.2018Headquarters
Allschwil, Basel-landschaftSupport
Our goal is to bring to the market the first oral, personalized therapy against Rheumatoid arthritis. We are developing the first drug potentially capable of reversing inflammation and bone erosion in a very well defined population of patients.
News
05.01.2021
Alibion ceases operations (startupticker.ch)
19.05.2020
Eleven Swiss start-ups on the virtual BIO Digital stage (startupticker.ch)
04.10.2019
A new cohort joins the BaseLaunch accelerator (startupticker.ch)
09.04.2019
Show all
Alibion kicks off pre-clinical studies to address Rheumatoid arthritis (startupticker.ch)